FDA Extends Deadline as Hidden Gluten Puts Regulatory Fine-Tuning Under the Spotlight

Why It Matters

Clearer gluten disclosures will reduce health risks for celiac patients and bolster confidence in a fast‑growing market, while forcing manufacturers to confront labeling and supply‑chain complexities.

Key Takeaways

• FDA extends gluten labeling RFI deadline to April 22 2026
• 5,000+ comments submitted, showing strong stakeholder interest
• Gluten‑free market valued $4.5 bn US, projected $33.6 bn globally
• Cross‑contact and hidden grains remain major labeling gaps
• Stricter disclosures could raise costs but protect brand trust

Pulse Analysis

The FDA’s latest Request for Information marks a pivotal shift in U.S. food labeling, moving beyond the narrow "gluten‑free" claim toward comprehensive transparency about hidden grains and cross‑contact. While the 20 ppm threshold aligns with international standards, the agency recognizes that many ingredients—malt extracts, flavorings, processing aids—mask gluten presence, creating uncertainty for the estimated 3 million Americans with celiac disease. By extending the comment period to April 2026, the FDA signals a willingness to incorporate consumer experiences and industry data, aiming to refine rules that keep pace with the expanding gluten‑free market, now valued at $4.5 bn domestically and projected to surpass $33 bn worldwide.

For manufacturers, the consultation introduces both challenges and opportunities. Detailed disclosure requirements could increase testing costs, especially for baked goods where gluten functions as a structural backbone. Yet brands that adopt third‑party certifications—such as the Gluten‑Free Certification Organization’s 10 ppm standard—may differentiate themselves in a crowded shelf space, turning compliance into a competitive advantage. Supply‑chain visibility becomes critical; firms must trace barley, rye, and potentially contaminated oats from farm to factory to meet any future labeling mandates, prompting investments in traceability technologies and tighter supplier contracts.

Globally, more than 80 countries already enforce stringent gluten labeling, putting U.S. regulators under international pressure to harmonize standards. As consumer demand for clean, transparent labels grows—driven not only by medical necessity but also by lifestyle trends—companies that proactively enhance label clarity can safeguard brand reputation and capture premium pricing. Conversely, vague or inconsistent disclosures risk eroding trust, prompting shoppers to switch to certified alternatives. The FDA’s RFI, therefore, is less about bureaucratic fine‑tuning and more about setting the groundwork for a resilient, trustworthy gluten‑free sector in an era of heightened consumer scrutiny.